Search results
Drug targeting clear cell renal cell carcinoma shows promising approach
Newswise· 4 days agoApril 23, 2024 – In a groundbreaking phase one clinical trial led by UT Southwestern Medical Center,...
Allogene secures $15 million grant for cancer trial By Investing.com
Investing.com· 24 hours agoThe TRAVERSE trial follows the Fast Track Designation granted by the...Administration in March 2022,...
The Top 3 Biotech Stocks to Buy in April 2024
InvestorPlace· 2 hours agoBiotech stocks are notorious for being some of the most volatile and unpredictable on the market. With clinical trials and FDA approvals creating...
New study provides genomic insights into kidney cancer risk
National Cancer Institute· 1 day agoIn a new analysis of genetic susceptibility to kidney cancer, an international team of researchers...
Analysts Expect Moderna's First-Quarter Sales To Plummet 95% — Is Moderna Stock A Sell?
Investor's Business Daily· 3 days agoOverall, 27.3% responded to the treatment. A total of 63.6% of patients had their disease under...
Innovent to Present Clinical Data of Multiple Novel Molecules at the 2024 ASCO Annual Meeting
ThePress.net· 2 days agoSAN FRANCISCO and SUZHOU, China, April 24, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the
Junshi Biosciences Announces NDA Acceptance in Hong Kong for Toripalimab
Morningstar· 2 days agoThe NDA is supported by results from JUPITER-02, a randomized, double-blind, placebo-controlled, multinational...
Merck (MRK) Q1 2024 Earnings Call Transcript
Motley Fool via Yahoo Finance· 2 days agoOutside the U.S., KEYTRUDA growth was driven by continued uptake in earlier-stage cancers, including high-risk, early stage, triple-negative breast...
Mirae Asset Global Investments Co. Ltd. Trims Stock Position in Iovance Biotherapeutics, Inc....
ETF DAILY NEWS· 4 days agoMirae Asset Global Investments Co. Ltd. trimmed its stake in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Free Report) by 3.4% during the fourth quarter, according to its most recent 13F filing ...
Cancer drug trial provides lessons for future
Medical Xpress· 2 days agoA cancer drug was found to be ineffective in preventing recurrence of kidney cancer in patients who recently underwent tumor removal surgery, according to a clinical trial published in the Journal ...
